Therapix Biosciences (Israel) Management Performance Evaluation

TRPX -- Israel Stock  

null 33.70  0.70  2.12%

Analysis of Therapix Biosciences manpower and management performance can provide insight into Therapix Biosciences stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with Therapix Biosciences future performance. Also please take a look at World Market Map.

Therapix Biosciences Management Effectiveness

The company has return on total asset (ROA) of (37.65) % which means that it has lost $37.65 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (216.64) % meaning that it generated substantial loss on money invested by shareholders.

Therapix Biosciences Stakeholders

Ascher Shmulewitz Chairman of the Board, Interim CEO
Guy Goldin Vice President - Finance
Doron Ami Vice President-Strategy
Adi ZuloffShani Vice President-Technologies
Oz Adler CFO
Tamar Kfir Director
Yafit Stark Independent Director
Ahmed Alimi Director
Itamar Shalit Director
Zohar Heiblum Independent Director
Abraham Meizler Director
Amit Berger External Director
Einat Zisman Director
Mark Groussman Director
Itzhak Kobrin Director
Eric So Director
Stephen Siems Director

Therapix Biosciences Leadership

Therapix Biosciences Top Executives

  Ascher Shmulewitz  Chairman
Chairman of the Board, Interim CEO
  Guy Goldin  President
Vice President - Finance

Therapix Biosciences Tenure Analysis

Therapix Biosciences Employment Tenure

Therapix Biosciences employes about 9 people. The company is managed by 17 executives with total tenure of roughly 80 years, averanging almost 4.0 years of service per executive having 0.0 employee per reported executive.

Therapix Biosciences Manpower Efficiency

Return on Therapix Biosciences Manpower

Net Loss Per Employee851.1 K
Net Loss Per Executive450.6 K
Also please take a look at World Market Map. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.